Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Open Access
- 1 January 2020
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (10), 1718-1723
- https://doi.org/10.7150/ijbs.45123
Abstract
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.Keywords
This publication has 58 references indexed in Scilit:
- Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly NeutralizingPLOS ONE, 2012
- Evidence for a Common Evolutionary Origin of Coronavirus Spike Protein Receptor-Binding SubunitsJournal of Virology, 2012
- Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potentialReviews in Medical Virology, 2011
- Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra virusesExpert Opinion on Biological Therapy, 2009
- Affinity maturation of antibodies assisted by in silico modelingProceedings of the National Academy of Sciences, 2008
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences, 2007
- SARS coronavirus and innate immunityVirus Research, 2007
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLoS Medicine, 2006
- A human SARS-CoV neutralizing antibody against epitope on S2 proteinBiochemical and Biophysical Research Communications, 2005
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004